Cox multivariate analysis for outcomes after HLA-identical BMT for patients with leukemia
| Outcomes (no. events) . | Variables increasing risk for outcomes . | Hazard ratio (95% CI), P . |
|---|---|---|
| Neutrophil recovery at d 40, n = 104 | ||
| Early/intermediate stage of disease | 2.27 (1.22-4.21), .01 | |
| Absence of TBI | 1.83 (1.22-2.75), .003 | |
| ABO compatibility | 1.67 (1.03-2.73), .04 | |
| Donor FcγRIIIb HNA-1a/HNA-1b | 1.77 (1.24-2.52), .002 | |
| Platelet recovery at d 180, n = 92 | ||
| Chronic leukemia | 2.08 (1.38-3.14), <.0001 | |
| Early stage of disease at transplantation | 1.94 (1.12-3.35), .02 | |
| Cell dose | 1.48/108 per kg (1.30-1.70), <.0001 | |
| ABO compatibility | 2.15 (1.45-3.19), .0002 | |
| Acute GVHD (II-IV) at d 100, n = 45 | ||
| Female donor to male recipient | 1.91 (1.05-3.47), .02 | |
| Donor IL-1Ra (absence of IL-1RN*2) | 2.07 (1.10-3.92), .017 | |
| First overall infections at d 180, n = 60 | ||
| Recipient-positive CMV serology | 2.82 (1.61-4.97), .0005 | |
| Recipient FcγIIa R-131 (HR or RR) | 1.92 (1.02-3.61), .04 | |
| First viral infection at day 180, n = 44 | ||
| Recipient-positive CMV serology | 10.34 (4.30-24.85), <.0001 | |
| Advanced stage of disease at transplantation | 4.49 (2.02-10.00), <.0001 | |
| Adult patients | 5.41 (1.47-19.97), .01 | |
| Donor-positive CMV to recipient-negative CMV serology | 2.28 (1.21-4.29), .01 | |
| First bacterial infection at d 180, n = 30 | ||
| Conditioning other than BuCY | 2.15 (1.08-4.51), .04 | |
| Major ABO incompatibility | 2.43 (1.16-5.09), .02 | |
| Donor MPO genotype AA+AG | 2.16 (1.08-4.32), .03 | |
| First fungal infection at d 180, n = 13 | ||
| Advanced stage of disease at transplantation | 6.51 (1.71-24.75), .006 | |
| Low CD34 cell dose | 1.41/106 per kg (1.01-1.97), .04 | |
| Chronic GVHD at 2 years, n = 50 of 95 at risk | ||
| Recipient IL-10 (GG) | 2.77 (1.10-6.95), .03 | |
| Recipient IL-1Ra (absence of IL-1RN*2) | 1.96 (1.06-3.60), .03 | |
| Recipient age, y | 1.61/10 (1.42-1.82), <.0001 | |
| Female donor | 1.92 (1.09-3.77), .02 | |
| TRM at d 180, n = 24 deaths | ||
| Advanced stage of disease | 4.80 (1.37-16.90), .01 | |
| Recipient age, y | 1.64/10 (1.15-2.35), .006 | |
| Donor MPO (AA) | 5.14 (1.71-15.44), .004 | |
| Donor FcγRIIIb HNA-1a/HNA-1a or HNA-1b/HNA-1b | 2.57 (1.01-6.62), .05 | |
| Survival at 5 y, n = 44 deaths | ||
| ABO major incompatibility | 2.45 (1.23-4.86), .01 | |
| Conditioning other than BuCY | 2.52 (1.35-4.71), .004 | |
| Recipient age, y | 1.31/10 (1.04-1.63), .02 |
| Outcomes (no. events) . | Variables increasing risk for outcomes . | Hazard ratio (95% CI), P . |
|---|---|---|
| Neutrophil recovery at d 40, n = 104 | ||
| Early/intermediate stage of disease | 2.27 (1.22-4.21), .01 | |
| Absence of TBI | 1.83 (1.22-2.75), .003 | |
| ABO compatibility | 1.67 (1.03-2.73), .04 | |
| Donor FcγRIIIb HNA-1a/HNA-1b | 1.77 (1.24-2.52), .002 | |
| Platelet recovery at d 180, n = 92 | ||
| Chronic leukemia | 2.08 (1.38-3.14), <.0001 | |
| Early stage of disease at transplantation | 1.94 (1.12-3.35), .02 | |
| Cell dose | 1.48/108 per kg (1.30-1.70), <.0001 | |
| ABO compatibility | 2.15 (1.45-3.19), .0002 | |
| Acute GVHD (II-IV) at d 100, n = 45 | ||
| Female donor to male recipient | 1.91 (1.05-3.47), .02 | |
| Donor IL-1Ra (absence of IL-1RN*2) | 2.07 (1.10-3.92), .017 | |
| First overall infections at d 180, n = 60 | ||
| Recipient-positive CMV serology | 2.82 (1.61-4.97), .0005 | |
| Recipient FcγIIa R-131 (HR or RR) | 1.92 (1.02-3.61), .04 | |
| First viral infection at day 180, n = 44 | ||
| Recipient-positive CMV serology | 10.34 (4.30-24.85), <.0001 | |
| Advanced stage of disease at transplantation | 4.49 (2.02-10.00), <.0001 | |
| Adult patients | 5.41 (1.47-19.97), .01 | |
| Donor-positive CMV to recipient-negative CMV serology | 2.28 (1.21-4.29), .01 | |
| First bacterial infection at d 180, n = 30 | ||
| Conditioning other than BuCY | 2.15 (1.08-4.51), .04 | |
| Major ABO incompatibility | 2.43 (1.16-5.09), .02 | |
| Donor MPO genotype AA+AG | 2.16 (1.08-4.32), .03 | |
| First fungal infection at d 180, n = 13 | ||
| Advanced stage of disease at transplantation | 6.51 (1.71-24.75), .006 | |
| Low CD34 cell dose | 1.41/106 per kg (1.01-1.97), .04 | |
| Chronic GVHD at 2 years, n = 50 of 95 at risk | ||
| Recipient IL-10 (GG) | 2.77 (1.10-6.95), .03 | |
| Recipient IL-1Ra (absence of IL-1RN*2) | 1.96 (1.06-3.60), .03 | |
| Recipient age, y | 1.61/10 (1.42-1.82), <.0001 | |
| Female donor | 1.92 (1.09-3.77), .02 | |
| TRM at d 180, n = 24 deaths | ||
| Advanced stage of disease | 4.80 (1.37-16.90), .01 | |
| Recipient age, y | 1.64/10 (1.15-2.35), .006 | |
| Donor MPO (AA) | 5.14 (1.71-15.44), .004 | |
| Donor FcγRIIIb HNA-1a/HNA-1a or HNA-1b/HNA-1b | 2.57 (1.01-6.62), .05 | |
| Survival at 5 y, n = 44 deaths | ||
| ABO major incompatibility | 2.45 (1.23-4.86), .01 | |
| Conditioning other than BuCY | 2.52 (1.35-4.71), .004 | |
| Recipient age, y | 1.31/10 (1.04-1.63), .02 |